Last update 06 Jun 2025

Nivolumab/Relatlimab/Hyaluronidase

Overview

Basic Info

Drug Type
Monoclonal antibody, Enzyme
Synonyms
Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination
Target
Hyaluronic acid x LAG3 x PD-1
Action
modulators, inhibitors, stimulants
Mechanism
Hyaluronic acid modulators, LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Metastatic melanoma
Inactive Indication-
Originator Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Related

4
Clinical Trials associated with Nivolumab/Relatlimab/Hyaluronidase
CTRI/2025/03/083121
/ Not yet recruitingPhase 3
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%
NCT06101134
/ Active, not recruitingPhase 2
A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous and Nivolumab Subcutaneous Versus Nivolumab Intravenous in Participants With Melanoma
CTIS2022-500967-11-00
/ RecruitingPhase 3
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma - CA224-127
100 Clinical Results associated with Nivolumab/Relatlimab/Hyaluronidase
Login to view more data
100 Translational Medicine associated with Nivolumab/Relatlimab/Hyaluronidase
Login to view more data
100 Patents (Medical) associated with Nivolumab/Relatlimab/Hyaluronidase
Login to view more data
100 Deals associated with Nivolumab/Relatlimab/Hyaluronidase
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 2
United States
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
06 Nov 2023
Metastatic melanomaPhase 2
Chile
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
06 Nov 2023
Metastatic melanomaPhase 2
Greece
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
06 Nov 2023
Metastatic melanomaPhase 2
Italy
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
06 Nov 2023
Metastatic melanomaPhase 2
Spain
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
06 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free